We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Indivior Plc | LSE:INDV | London | Ordinary Share | GB00BN4HT335 | ORD USD0.50 |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
14.00 | 1.50% | 945.00 | 944.50 | 946.00 | 949.50 | 926.00 | 935.00 | 31,491 | 10:10:20 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Pharmaceutical Preparations | 1.09B | 2M | 0.0154 | 612.66 | 1.21B |
Date | Subject | Author | Discuss |
---|---|---|---|
24/1/2023 11:04 | Ha I was thinking the same thing yesterday. This is by far and away my best performing share over the last 3 years | villarich | |
24/1/2023 00:00 | This should be how all our investments should look. I'm minded to print it out and frame it. | casholaa | |
23/1/2023 23:16 | The 3 year chart is a thing of beauty. | villarich | |
15/1/2023 10:46 | PE for 2022 won’t be anywhere near that level due to fantastic growth being delivered and expected to continue. EPS through 3 quarters is already 75p so PE will be more like 19x Stick another 80% growth for 2023 on top line and the forward PE falls through the floor Nasdaq listing to come imminently too is seeing institutional investors get on board in advance of that GLA … DYOR | youngers | |
15/1/2023 10:37 | great looking chart in nice steady uptrend with next resistance at about 2100 level . BUT not sure why with a p/e of about 89 and high gearing and maybe someone who studies the fundamentals can explain it ? However , as a chartist I mainly trade on what chart tells me but like a company to have good fundamentals . | arja | |
30/12/2022 09:01 | Looking set for a great finish to 2022 here. Massive growth being delivered and US listing to look forward to in 2023. GLA | youngers | |
08/12/2022 16:58 | Closing price distorted again by rogue trade | youngers | |
07/12/2022 18:32 | Yes I think you are right. Though forgive me, Once is enough though! | gregmorg | |
07/12/2022 17:22 | If fell into the 30's I think | baddeal | |
07/12/2022 13:35 | And what goes around comes around Greg......the first shall be last and the last shall be first!This has been a splendid recovery over the last couple of years.The shares are 350 odd in old money and i think the stock fell as low as 50p at one point. | steeplejack | |
07/12/2022 11:52 | Ah, Steeplejack we remember those days eh! So, who knows, we might see those numbers again. From what I have briefly scanned it looks rather more encouraging so here’s hoping. I assume I will be able to see parts of the presentation and slides in a few days time when back at base. | gregmorg | |
07/12/2022 11:23 | The shares all time high was set around May 2018.In new money,that high was around £24. | steeplejack | |
07/12/2022 07:52 | 07 December 2022 Indivior Capital Markets Day Highlights Strategy for Shareholder Value Creation and Attractive Medium-Term Profitable Growth Outlook - Peak Annual Net Revenue Potential for SUBLOCADE (R) Increased to >$1.5 Billion - Attractive and Scalable Business Outlined - Expects Strong Net Revenue Growth and Operating Margin Expansion Over the Medium-term - Disciplined Approach to Capital Allocation Maintained - NASDAQ Listing Targeted for Spring 2023 This Release Contains Inside Information. Slough, UK, and Richmond, VA, December 7, 2022 - Indivior PLC (LON: INDV) will hold a Capital Markets Day today in New York City. The event will be hosted by Mark Crossley, Chief Executive Officer, along with members of the Indivior executive leadership team and will detail the Company's strategic growth plans and roadmap for delivering long-term shareholder value. "We have made tremendous progress executing on our strategic priorities," said Mark Crossley. "We are the pioneer and global leader in addiction treatment and science and are well-positioned to transform the lives of the increasing number of patients affected by the opioid crisis, one of the most urgent public health emergencies of our time. Today, my team and I are excited to provide a deep review of our business and to highlight the compelling opportunities we have to innovate in the treatment of addiction and serious mental illness while delivering profitable growth and significant value creation for shareholders." -- Increases SUBLOCADE peak annual net revenue (NR) expectations to >$1.5 billion Indivior expects SUBLOCADE(R) (buprenorphine extended-release) injection to achieve a NR run rate of $1 billion by the end of 2025, driven by its focus on further developing the Organized Health Systems (OHS) channel and pursuing the large opportunity in the U.S. Justice System. Longer term, based on the expected positive market dynamics for buprenorphine medication-assisted treatment (BMAT) and on continued execution against its OHS strategy, Indivior now expects to deliver SUBLOCADE peak potential NR of >$1.5 billion. -- Expects to achieve attractive double-digit % NR compounded annual growth rate (CAGR) over the medium-term Indivior expects to achieve a double-digit percentage NR CAGR over the medium-term, driven primarily by SUBLOCADE in the United States and growing NR contribution from PERSERIS(R) (risperidone for extended-release injection). Within this outlook, which is based on its current business portfolio, Indivior also expects a return to NR growth in the Rest of the World driven by new products SUBLOCADE (SUBUTEX (R) PR) and SUBOXONE (R) (buprenorphine/nalox -- Operating margin expansion opportunity from scalable business model Indivior expects to achieve significant operating margin expansion over the medium-term driven by an improving gross margin and focused management of operating expenses. Following the significant structural growth investments behind SUBLOCADE and PERSERIS in the past two years, selling, general and administrative (SG&A) expenses are expected to grow at a more moderate pace and to decline as a percentage of NR. This impact is expected to be partly offset by an increase in R&D expenses as a percentage of NR towards industry benchmarks as the Company seeks to build a strong and balanced pipeline focused on addiction treatments. -- Disciplined capital allocation approach focused on driving growth and potential returns of excess cash In the past two years, Indivior's healthy balance sheet and improved cash flow have supported a balanced approach towards capital allocation, focused on investment in key growth priorities, diversifying the business, delivering shareholder returns and meeting other stakeholder obligations. The recently announced definitive agreement to acquire Opiant Pharmaceuticals, Inc. (NASDAQ: OPNT) is indicative of Indivior's commitment to diversify its product portfolio and to expand its global leadership in addiction treatment and science. -- Listing on NASDAQ targeted for the Spring of 2023 At its Extraordinary General Meeting (EGM) in September of this year, Indivior received strong support from its shareholders for an additional share listing in the United States. Having carefully evaluated the available options, Indivior has chosen NASDAQ as its U.S. trading venue. The additional listing is expected to elevate Indivior's profile in the Company's largest market and to attract a broader group of biopharma-focused investors and analysts. The Group reiterates its FY 2022 guidance published on October 27, 2022. Event Details Today's event will begin at 8:30am EST and conclude at 12:30pm EST. Due to limited availability, in-person participation is limited to institutional investors and analysts. For those wishing to attend in person, please RSVP to investorrelations@in Further details can be found at cmd.indivior.com To access the live webcast, please click INDV CMD 2022 . A webcast replay will be available after the event has concluded. The person responsible for making this announcement is Kathryn Hudson, Company Secretary. | grupo guitarlumber | |
05/12/2022 16:56 | Something funny going on here. Late reported trade every evening making the closing price look much lower than reality. | youngers | |
02/12/2022 08:53 | And by the way, 'shorting' is just another market strategy - it doesn't make a company "not nice". If shorters get it wrong they lose money, just like long only funds can do. | redwing1 | |
02/12/2022 08:49 | Timmy11 - It might help if you actually understood shorting. The clue is in the name and it means selling stock you don't have in the expectation of buying it back at a lower price later on for a profit. Therefore Blackrock are simply buying right now. Whether they end up 'pumping and dumping' is another story - we shall see. | redwing1 | |
23/11/2022 18:15 | A good observation | steeplejack | |
23/11/2022 15:35 | i am wary of BlackRock, they usually buy to short... not a nice company | timmy11 | |
23/11/2022 11:57 | GLA. DYOR. | casholaa | |
23/11/2022 08:21 | SocGen have upped their interest by around 1.25% to over 5% while Blackrock now have a similarly sized declarable stake.All very encouraging. | steeplejack | |
22/11/2022 22:53 | There's two rns not showing up here ...you may want to track them down. :o) | casholaa | |
21/11/2022 16:32 | Good to see this finally break the £17 mark today. Hopefully set for another leg higher from here | youngers | |
15/11/2022 09:41 | Yup, the odd "extra string to the bow" does not go amiss. Although small (currently!) it's potentially a nice acquisition. | gregmorg | |
14/11/2022 13:58 | Very nice. | casholaa | |
14/11/2022 08:30 | Indivior to buy US overdose treatment firm Opiant for $145m Mon, 14th Nov 2022 07:05 Sharecast News (Sharecast News) - UK-based drug company Indivior said it would pay $145m for Opiant Pharmaceuticals which produces treatments to overcome opioid addiction. The price equates to $20 a share, with an extra $8 per share contingent on Opiant's ability to gain approvals and revenue for an overdose-reversal medication in late-stage development. Opiant contributed to the development of the formulation of Narcan nasal spray, a treatment to reverse opioid overdose. It is also developing potential treatments for alcohol drinking and cravings acute cannabinoid overdose. The US government has pledged $1.5bn to treat its growing the overdose crisis and billions from lawsuit settlements against pharmaceutical companies that made the opioids have begun flowing to local governments to combat deaths. Reporting by Frank Prenesti for Sharecast.com | the grumpy old men |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions